Sažetak
Uvod/Cilj. Polimorfizmi gena koji kodiraju transporter P-glikoprotein i najvažnije enzime za farmakokinetiku takrolimusa mogu imati značajan uticaj koji se odražava na koncentracije ovog leka u krvi. Cilj ovog ispitivanja bio je da se ispita učestalost polimorfizma gena CYP3A5, CYP3A4 i ABCB1 kod bolesnika sa transplantiranim bubregom, po prvi put u našem centru za transplantaciju. Metode. Urađena je prospektivna studija preseka koja je obuhvatila 211 bolesnika sa urađenom transplantacijom bubrega u Centru za transplantaciju solidnih organa Vojnomedicinske akademije u Beogradu. U studiju su bili uključeni bolesnici oba pola, starosti od 22 do 69 godina, bele rase i na imunosupresivnom režimu koji uključuje takrolimus. Urađena je genotipizacija CYP3A5 6986A>G (*3 ili *1, rs776746), CYP3A4 -392A>G (*1 ili *1B, rs2740574) i ABCB1 3435C>T (rs1045642) korišćenjem TaqMan® eseja za određivanje pojedinačnih nukleotidnih polimorfizama. Rezultati. Većina naših bolesnika (94,8%) imala je funkcionalan CYP3А4 enzim, dok je kod 87,7% od svih naših bolesnika CYP3A5 bio sa oštećenom aktivnošću. S druge strane, kod oko trećine (31,3%) bolesnika ABCB1 transporter bio je funkcionalan. Zaključak. Ukupno 84,8% naših bolesnika imalo je istovremeno CYP3A5*3*3 genotip, povezan sa smanjenom CYP3A5 aktivnošću, i CYP3A4*1*1/*1*1B genotip, povezan sa funkcionalnom formom CYP3A4 enzima, dok je od svih bolesnika sa smanjenom CYPA5 enzimskom aktivnošću 68,7% imalo smanjenu aktivnost ABCB1 transportera. Međutim, buduće studije su neophodne kako bi se pokazao uticaj ovih genskih polimorfizama na koncentraciju takrolimusa u krvi bolesnika nakon transplantacije bubrega.
Ključne reči
Array
Array
Array
Array
Array
Array
Array
Array
Array
Array
Array
Array
Array
Array
Array
Reference
Ponticelli C. Present and future of immunosuppressive therapy in kidney transplantation. Transplant Proc 2011; 43(6): 2439−40.
Provenzani A, Santeusanio A, Mathis E, Notarbartolo M, Labbozzetta M, Poma P, et al. Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients. World J Gastroenterol 2013; 19(48): 9156−73.
Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995; 29(6): 404−30.
Undre N, Stevenson P, Schäfer A. Pharmacokinetics of tacro-limus: clinically relevant aspects. Transplant Proc 1999; 31(7A): 21S−4S.
Krensky MA, Bennett MW, Vincenti F. Immunosuppressants, to-lerogens and immunostimulants. In: Brunton LL, editor. Goodman & Gilman's The pharmacological Basis of Thera-peutics. New York: McGraw-Hill Book Company; 2011. p. 1005−31.
Danesi R, Mosca M, Boggi U, Mosca F, del Tacca M. Genetics of drug response to immunosuppressive treatment and prospects for personalized therapy. Mol Med Today 2000; 6(12): 475−82.
Yagil Y, Yagil C. Insights into pharmacogenomics and its im-pact upon immunosuppressive therapy. Transpl Immunol 2002; 9(2−4): 203−9.
Vavic N, Rancic N, Dragojevic-Simic V, Draskovic-Pavlovic B, Bo-konjic D, Ignjatovic L, et al. The influence of comedication on tacrolimus blood concentration in patients subjected to kidney transplantation: a retrospective study. Eur J Drug Metab Pharmacokinet 2014; 39(4): 243−53.
Rancic N, Dragojevic-Simic V, Vavic N, Kovacevic A, Segrt Z, Draskovic-Pavlovic B, et al. Tacrolimus concentration/dose ratio as a therapeutic drug monitoring strategy: The influence of gender and comedication. Vojnosanit Pregl 2015; 72(9): 813−22.
Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74(3): 245−54.
Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Se-quence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27(4): 383−91.
Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacoki-netics and pharmacodynamics of calcineurin inhibitors: Part II. Clin Pharmacokinet 2010; 49(4): 207−21.
Tang H, Xie H, Yao Y, Hu Y. Lower tacrolimus daily dose re-quirements and acute rejection rates in the CYP3A5 nonex-pressers than expressers. Pharmacogenet Genomics 2011; 21(11): 713−20.
Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002; 12(2): 121−32.
Bozina N, Bradamante V, Lovrić M. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arh Hig Rada Toksi-kol 2009; 60(2): 217−42.
Chakkera HA, Chang Y, Bodner JK, Behmen S, Heilman RL, Reddy KS, et al. Genetic differences in Native Americans and tacrolimus dosing after kidney transplantation. Transplant Proc 2013; 45(1): 137−41.
Westlind A, Löfberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region. Biochem Biophys Res Commun 1999; 259(1): 201−5.
Elens L, Bouamar R, Hesselink DA, Haufroid V, van der Heiden IP, van Gelder T, et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharma-cokinetics in kidney transplant recipients. Clin Chem 2011; 57(11): 1574−83.
Sinues B, Vicente J, Fanlo A, Vasquez P, Medina JC, Mayayo E, et al. CYP3A5*3 and CYP3A4*1B allele distribution and genotype combinations: differences between Spaniards and Central Americans. Ther Drug Monit 2007; 29(4): 412−6.
Macphee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002; 74(11): 1486−9.
Herrero MJ, Sánchez-Plumed J, Galiana M, Bea S, Marqués MR, Aliño SF. Influence of pharmacogenetic polymorphisms in routine immunosuppression therapy after renal transplanta-tion. Transplant Proc 2010; 42(8): 3134−6.
Cheung CY. Pharmacogenetics and renal transplantation. In: Trzcinski M , editor. Kidney transplantation- new perspectives. Rijeka, Croatia: InTech; 2011. p. 147−62.
Chen Y, Han L, Xue F, Shen C, Lu J, Yang T, et al. Persona-lized Tacrolimus Dose Requirement by CYP3A5 but Not ABCB1 or ACE Genotyping in Both Recipient and Donor after Pediatric Liver Transplantation. PLoS ONE 2014; 9(10): e109464.
Zhang J, Zhang H, Ding X, Ma S, Miao L. Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers. Eur J Clin Pharmacol 2013; 69(4): 807−12.
de Jonge H, Metalidis C, Naesens M, Lambrechts D, Kuypers DR. The P450 oxidoreductase *28 SNP is associated with low ini-tial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics 2011; 12(9): 1281−91.
Elens L, Capron A, van Schaik RH, De MM, De PL, Eddour DC, et al. Impact of CYP3A4*22 allele on tacrolimus pharmacoki-netics in early period after renal transplantation: toward up-dated genotype-based dosage guidelines. Ther Drug Monit 2013; 35(5): 608−16.